Trial
NCT04151225
Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Crohns Disease
Intervention
GSK2330811
Why stopped
Internal sponsor decision to terminate project in Crohn's disease due to potential narrow therapeutic window. No subjects were enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-14